News

The protocol was filed under the company’s existing IND for ORMD-0801 to include both type 1 and type 2 diabetes indications. The double-blind, randomized, placebo controlled, seven-day trial

The company has partnered with Ludwig Cancer Research over the last year to identify small molecule inhibitors of the enzyme that display nanomolar potency, good selectivity, favorable pharmacokinetics

With this new capability, Fluxion can now provide clinical sample procurement that includes fresh blood draws from a wide range of cancer indications and tumor subtype profiles, such

The Institute of Biomedical Research is an ambitious biomedical business venture whose activities extend from highly diversified scientific research and sophisticated services research and development, quality control and

GAMES-RP is a Phase 2 randomized, double blind, placebo controlled, multi-center study of RP-1127 in patients with a severe ischemic stroke who are likely to experience clinically significant

NOxCureCF is a specialized formulation of inhaled Nitric Oxide (NO) targeting the Pseudomonas and the Staphylococcus aureus bacteria, the most common bacteria found in CF patients’ lungs and

The purpose of the study is to validate the effectiveness of the test methods developed by DiagnosTear in the tears of healthy subjects as well as patients with

Last week Nuvilex announced it will, in fact, use the unique and proprietary cellulose-based live-cell encapsulation technology, Cell-in-a-Box, to develop treatments for serious and deadly forms of cancer.

HoFH impairs the function of the receptor responsible for removing LDL-C (bad cholesterol) from the body and the loss of LDL receptor function results in extreme elevation of